公开(公告)号：US20220267299A1

公开(公告)日：2022-08-25

申请号：US17610321

申请日：2020-05-12

Applicant: NOVARTIS AG

Inventor： Cornelius Stephen HARLACHER ,  Zaixing LI ,  Liladhar Murlidhar Waykole

IPC: C07D401/12

Abstract: The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a N pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition CA of the present invention can be used as a medicament, in particular for the treatment of cancers.

公开(公告)号：US20180273522A1

公开(公告)日：2018-09-27

申请号：US15762724

申请日：2016-09-20

Applicant: Novartis AG

Inventor： Eric AUBIN ,  Anthony CASAREZ ,  Andreas FISCH ,  Zaixing LI ,  Mika LINDVALL ,  Heinz Ernst MOSER ,  Michael MUTZ ,  Folkert RECK ,  Bernd Ulrich RIEBESEHL ,  Marc SCHOENHENTZ ,  Vijay SETHURAMAN ,  Robert Lowell SIMMONS

IPC: C07D417/14 ,  A61P31/04

CPC classification number: C07D417/14 ,  A61P31/04 ,  C07B2200/13

Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.